Patents
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
01/2014
01/09/2014US20140008264 Biodegradable Natural Films Based on Co-Products Derived from Industrial-Scale Seed-Treatment Processes
01/08/2014EP2682128A1 Medicinal agent for inhibiting metastasis of malignant tumor
01/08/2014EP2682114A1 Milnacipran for the long-term treatment of fibromyalgia syndrome
01/08/2014EP2682111A1 Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
01/08/2014EP2680858A1 Proteasome inhibitor delanzomib for use in the treatment of lupus
01/08/2014EP2680841A1 Use of glycopyrrolate for treating tachycardia
01/08/2014EP2680821A2 Liposome formulation comprising an anti-tumour active substance, method for its preparation and pharmaceutical compositions comprising it
01/08/2014CN103501800A Beautiful-skin-promoting agent and use thereof
01/08/2014CN103501785A Csf-1r inhibitors for treatment of brain tumors
01/08/2014CN103501781A Use of glycopyrrolate for treating tachycardia
01/08/2014CN103501772A Composition comprising diindolylmethane and retinoid to treat skin condition
01/08/2014CN103495179A Polymer albumin nanosphere as well as preparation method and applications of nanosphere
01/08/2014CN103495174A Multi-effect external preparation used for treating superficial skin injury and application thereof
01/08/2014CN103495173A Trauma therapy
01/08/2014CN103495172A Medicament for treating amphetamine type stimulant dependency and mixed dependency of amphetamine type stimulants and opiates substances
01/08/2014CN103495171A Pharmaceutical and cosmetic formulations for treating fingernails
01/08/2014CN103495170A Method of reducing multi-drug resistance using inositol tripyrophosphate
01/08/2014CN103495169A Methods and compositions for treatment and control of multiple myeloma
01/08/2014CN103494817A Methods and compoistions used for treatment and control of multiple myeloma
01/08/2014CN103494765A Porous silicon drug-eluting particles
01/08/2014CN103493799A Improved organ protection, preservation and recovery
01/08/2014CN102772424B Application of neohesperidin in preparing of diabetes preventive treatment medicines
01/08/2014CN102688223B Anti-cancer drug-loading nanofiber film and preparation method thereof
01/08/2014CN101932939B Marker for determination of sensitivity to anti-cancer agent
01/08/2014CN101547698B Intra-mammary teat sealant formulation and method of using same to reduce or eliminate visual defects in aged cheeses
01/07/2014US8623874 Method of treating neurodegenerative diseases
01/07/2014US8623864 Thioridazine and derivatives thereof for reversing anti-microbial drug-resistance
01/07/2014US8623857 N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1
01/07/2014US8623851 Formoterol/steroid bronchodilating compositions and methods of use thereof
01/07/2014US8623847 Compositions for treatment of inflammatory diseases
01/07/2014US8623833 Compositions and methods for enhancing drug delivery across and into epithelial tissues
01/07/2014US8623819 Therapy for complications of diabetes
01/07/2014US8623422 Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions
01/07/2014US8623393 Biomatrix structural containment and fixation systems and methods of use thereof
01/07/2014US8623384 Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of acute myelogenous leukemia
01/07/2014US8623349 Systems, methods and microrganisms for antibody production with type III secretion system
01/07/2014CA2664915C Pharmaceutical composition comprising phenylamidine derivative and method of using the pharmaceutical composition in combination with antifungal agent
01/07/2014CA2594187C Method for producing probiotically derived compounds
01/07/2014CA2461372C Dna sequences for human angiogenesis genes
01/07/2014CA2286798C Alpha-o-linked glycoconjugates with clustered(2,6)-st epitopes, methods of preparation and uses thereof
01/03/2014WO2014004902A2 Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
01/03/2014WO2014004674A2 Methods for treating hcv
01/03/2014WO2014004470A1 Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using pi3 kinase inhibitors
01/03/2014WO2014003155A1 Pharmaceutical composition containing compound having thrombopoietin receptor agonistic activity
01/03/2014WO2014003116A1 Nutritional composition
01/03/2014WO2014001882A1 Composition comprising a sesterterpene and use thereof as antibiotic and antifungal adjuvant
01/03/2014WO2014001314A1 Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
01/03/2014CA2877874A1 Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using pi3 kinase inhibitors
01/03/2014CA2876496A1 Methods for treating hcv
01/02/2014US20140007292 Novel Insecticidal Proteins and Methods for Their Use
01/02/2014US20140005262 Racecadotril lipid compostions
01/02/2014US20140005261 Racecadotril liquid compositions
01/02/2014US20140005256 Formulations with anti-tumour action
01/02/2014US20140005255 Agonists Of Toll Like Receptor For Treating Cardiovasuclar Disease And Obesity
01/02/2014US20140005249 Nkx2.2 inhibitors as drugs
01/02/2014US20140005226 Phenoxyethyl piperidine compounds
01/02/2014US20140005225 Method of inhibiting c-kit kinase
01/02/2014US20140005215 Selective Opioid Compounds
01/02/2014US20140005211 Derivatives of pyrazole-substituted amino-heteroaryl compounds
01/02/2014US20140005199 Implant for the controlled release of pharmaceutically active agents
01/02/2014US20140005192 Inhibitors of influenza viruses replication
01/02/2014US20140005178 Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
01/02/2014US20140005177 Pyridinyl- and pyrazinyl-methyloxy-aryl derivatives useful as inhibitors of spleen tyrosine kinase (syk)
01/02/2014US20140005168 5-azaindazole compounds and methods of use
01/02/2014US20140005155 Organic compounds
01/02/2014US20140005154 6,7-Dihydrothieno[3,2-d]pyrimidine for the Treatment of Inflammatory Diseases
01/02/2014US20140005151 Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
01/02/2014US20140005150 3,4-diarylpyrazoles as protein kinase inhibitors
01/02/2014US20140005139 Cellooligosaccharide-containing composition
01/02/2014US20140005136 Novel compounds and compositions and methods of use
01/02/2014US20140005122 Gemcitabine combination therapy
01/02/2014US20140005111 Injectable delivery system for heparan-binding growth factors
01/02/2014US20140005108 Method for decreasing low density lipoprotein levels
01/02/2014US20140005104 Polyheterocyclic compounds highly potent as hcv inhibitors
01/02/2014US20140005096 Methods of treating inflammation
01/02/2014US20140004199 Drug carrier for tumor-targeted therapy, its preparation method and its use
01/02/2014US20140004192 Pharmaceutical formulations of indibulin and uses thereof
01/02/2014US20140004190 Solid Dosage Forms of Bendamustine
01/02/2014US20140004181 Compositions and methods for exosome targeted expression
01/02/2014US20140004175 Angiopoietin derived peptides
01/02/2014US20140004174 Selective inhibitors of histone deacetylase
01/02/2014US20140004151 Antigens and Epitopes Derived From Mycobacterium Tuberculosis
01/02/2014US20140004124 Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma
01/02/2014US20140004119 Agonistic antibodies to trkc receptors and uses thereof
01/02/2014US20140004118 Clostridium difficile antibodies
01/02/2014US20140004116 Methods of preventing or treating pain using anti-ngf antibodies
01/02/2014US20140004115 Methods of preventing or treating pain using anti-ngf antibodies that selectively inhibit the association of ngf with trka, without affecting the association of ngf with p75
01/02/2014US20140004112 Therapeutic Peptides
01/02/2014US20140004110 Anti cd37 antibodies
01/02/2014US20140004104 Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
01/02/2014US20140004101 Smac peptidometics useful as iap inhibitors
01/02/2014US20140004100 Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
01/02/2014US20140004082 Methods for treating leukemia and disorders mediated by cbfbeta and runx1 proteins
01/02/2014US20140004081 Re-Directed Immunotherapy
01/02/2014US20140004078 Immunoconjugates with an Intracellularly-Cleavable Linkage
01/02/2014US20140004077 Method for treating cervical cancer
01/02/2014US20140004038 Combinatorial therapy
01/01/2014EP2679230A1 Pharmaceutical formulation comprising compounds of the jasmonate family
01/01/2014EP2679224A1 Nitro oleic acid modulation of type II diabetes
01/01/2014EP2679223A1 Treatments using citrulline
1 ... 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 ... 1151